236 related articles for article (PubMed ID: 31715422)
21. Kirsten rat sarcoma viral oncogene homolog G12C mutant advanced non-small-cell lung cancer treated with MEK1/2 inhibitor trametinib: a case report.
Jiang Y; Liu X; Lv DL; Zhao XL
Anticancer Drugs; 2022 Jan; 33(1):e752-e755. PubMed ID: 34387588
[TBL] [Abstract][Full Text] [Related]
22. Preclinical assessment of MEK1/2 inhibitors for neurofibromatosis type 2-associated schwannomas reveals differences in efficacy and drug resistance development.
Fuse MA; Dinh CT; Vitte J; Kirkpatrick J; Mindos T; Plati SK; Young JI; Huang J; Carlstedt A; Franco MC; Brnjos K; Nagamoto J; Petrilli AM; Copik AJ; Soulakova JN; Bracho O; Yan D; Mittal R; Shen R; Telischi FF; Morrison H; Giovannini M; Liu XZ; Chang LS; Fernandez-Valle C
Neuro Oncol; 2019 Mar; 21(4):486-497. PubMed ID: 30615146
[TBL] [Abstract][Full Text] [Related]
23. Study of Molecular Mechanism of the Interaction Between MEK1/2 and Trametinib with Docking and Molecular Dynamic Simulation.
Hashemzadeh S; Ramezani F; Rafii-Tabar H
Interdiscip Sci; 2019 Mar; 11(1):115-124. PubMed ID: 30465279
[TBL] [Abstract][Full Text] [Related]
24. Trametinib.
Zeiser R
Recent Results Cancer Res; 2014; 201():241-8. PubMed ID: 24756797
[TBL] [Abstract][Full Text] [Related]
25. Improved survival with MEK inhibition in BRAF-mutated melanoma.
Flaherty KT; Robert C; Hersey P; Nathan P; Garbe C; Milhem M; Demidov LV; Hassel JC; Rutkowski P; Mohr P; Dummer R; Trefzer U; Larkin JM; Utikal J; Dreno B; Nyakas M; Middleton MR; Becker JC; Casey M; Sherman LJ; Wu FS; Ouellet D; Martin AM; Patel K; Schadendorf D;
N Engl J Med; 2012 Jul; 367(2):107-14. PubMed ID: 22663011
[TBL] [Abstract][Full Text] [Related]
26. EGFR and HER2 signals play a salvage role in MEK1-mutated gastric cancer after MEK inhibition.
Mizukami T; Togashi Y; Sogabe S; Banno E; Terashima M; De Velasco MA; Sakai K; Fujita Y; Tomida S; Nakajima TE; Boku N; Nishio K
Int J Oncol; 2015 Aug; 47(2):499-505. PubMed ID: 26081723
[TBL] [Abstract][Full Text] [Related]
27. Response and Resistance to Trametinib in MAP2K1-Mutant Triple-Negative Melanoma.
Krebs FS; Moura B; Missiaglia E; Aedo-Lopez V; Michielin O; Tsantoulis P; Bisig B; Trimech M; Zoete V; Homicsko K
Int J Mol Sci; 2023 Feb; 24(5):. PubMed ID: 36901951
[TBL] [Abstract][Full Text] [Related]
28. MAP2K1 and MAP3K1 mutations in Langerhans cell histiocytosis.
Nelson DS; van Halteren A; Quispel WT; van den Bos C; Bovée JV; Patel B; Badalian-Very G; van Hummelen P; Ducar M; Lin L; MacConaill LE; Egeler RM; Rollins BJ
Genes Chromosomes Cancer; 2015 Jun; 54(6):361-8. PubMed ID: 25899310
[TBL] [Abstract][Full Text] [Related]
29. Factors influencing the CNS distribution of a novel MEK-1/2 inhibitor: implications for combination therapy for melanoma brain metastases.
Vaidhyanathan S; Mittapalli RK; Sarkaria JN; Elmquist WF
Drug Metab Dispos; 2014 Aug; 42(8):1292-300. PubMed ID: 24875464
[TBL] [Abstract][Full Text] [Related]
30. Targeting oncogenic Raf protein-serine/threonine kinases in human cancers.
Roskoski R
Pharmacol Res; 2018 Sep; 135():239-258. PubMed ID: 30118796
[TBL] [Abstract][Full Text] [Related]
31. FDA Approval Summary: Dabrafenib and Trametinib for the Treatment of Metastatic Non-Small Cell Lung Cancers Harboring
Odogwu L; Mathieu L; Blumenthal G; Larkins E; Goldberg KB; Griffin N; Bijwaard K; Lee EY; Philip R; Jiang X; Rodriguez L; McKee AE; Keegan P; Pazdur R
Oncologist; 2018 Jun; 23(6):740-745. PubMed ID: 29438093
[TBL] [Abstract][Full Text] [Related]
32. Physapubescin B enhances the sensitivity of gastric cancer cells to trametinib by inhibiting the STAT3 signaling pathway.
Dai C; Shen L; Jin W; Lv B; Liu P; Wang X; Yin Y; Fu Y; Liang L; Ma Z; Zhang X; Wang Y; Xu D; Chen Z
Toxicol Appl Pharmacol; 2020 Dec; 408():115273. PubMed ID: 33035574
[TBL] [Abstract][Full Text] [Related]
33. Allosteric Kinase Inhibitors Reshape MEK1 Kinase Activity Conformations in Cells and In Silico.
Fleischmann J; Feichtner A; DeFalco L; Kugler V; Schwaighofer S; Huber RG; Stefan E
Biomolecules; 2021 Mar; 11(4):. PubMed ID: 33808483
[TBL] [Abstract][Full Text] [Related]
34. Response to Trametinib of a Pulmonary Langerhans Cell Histiocytosis Harboring a MAP2K1 Deletion.
Lorillon G; Jouenne F; Baroudjian B; de Margerie-Mellon C; Vercellino L; Meignin V; Lebbe C; Vassallo R; Mourah S; Tazi A
Am J Respir Crit Care Med; 2018 Sep; 198(5):675-678. PubMed ID: 29694792
[No Abstract] [Full Text] [Related]
35. Preclinical activity of EGFR and MEK1/2 inhibitors in the treatment of biliary tract carcinoma.
Cavalloni G; Peraldo-Neia C; Varamo C; Chiorino G; Sassi F; Aglietta M; Leone F
Oncotarget; 2016 Aug; 7(32):52354-52363. PubMed ID: 27429047
[TBL] [Abstract][Full Text] [Related]
36. MAPK inhibitors induce serine peptidase inhibitor Kazal type 1 (SPINK1) secretion in BRAF V600E-mutant colorectal adenocarcinoma.
Räsänen K; Dang KX; Mustonen H; Ho TH; Lintula S; Koistinen H; Stenman UH; Haglund C; Stenman J
Mol Oncol; 2018 Feb; 12(2):224-238. PubMed ID: 29193645
[TBL] [Abstract][Full Text] [Related]
37. Adjusting for treatment switching in the METRIC study shows further improved overall survival with trametinib compared with chemotherapy.
Latimer NR; Bell H; Abrams KR; Amonkar MM; Casey M
Cancer Med; 2016 May; 5(5):806-15. PubMed ID: 27172483
[TBL] [Abstract][Full Text] [Related]
38. Trametinib radiosensitises RAS- and BRAF-mutated melanoma by perturbing cell cycle and inducing senescence.
Schick U; Kyula J; Barker H; Patel R; Zaidi S; Gregory C; Hafsi H; Roulstone V; Deutsch E; McLaughlin M; Harrington K
Radiother Oncol; 2015 Nov; 117(2):364-75. PubMed ID: 26163092
[TBL] [Abstract][Full Text] [Related]
39. Trametinib in the treatment of melanoma.
Thota R; Johnson DB; Sosman JA
Expert Opin Biol Ther; 2015 May; 15(5):735-47. PubMed ID: 25812921
[TBL] [Abstract][Full Text] [Related]
40. "RB-reactivator screening" as a novel cell-based assay for discoveries of molecular targeting agents including the first-in-class MEK inhibitor trametinib (trade name: Mekinist).
Sakai T
Pharmacol Ther; 2022 Aug; 236():108234. PubMed ID: 35732246
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]